References
- ParkinDM,WhelanSL, Ferlay J, etal. Cancer incidence in five continents. IARC Scientific Publications No. 143. Lyon: IARC, 1997
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71 https://doi.org/10.1126/science.7545954
- Wooster R, BignellG,Lancaster J, et al. Identification of the breastcancersusceptibilitygeneBRCA2. Nature 1995;378:789-792 https://doi.org/10.1038/378789a0
- Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in BRCA1 breast and ovarian cancer susceptibility gene. J Am Med Assoc 1995; 273:535-541 https://doi.org/10.1001/jama.273.7.535
- Struewing JP,HangeP,WacholderS. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997:336:1401-1408
- Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F , Naguchi T, Baily C. Germline mutation at BRCA1 affects the histologic grade in hereditary breast cancer. Cancer Res 1996;56:471-474
- VerhoogLC,BrekelmansCTM,SeynaeveC,etal. Survival and tumor characteristics of Breast cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-321 https://doi.org/10.1016/S0140-6736(97)07065-7
- Armes JE, Trute L, White D, et al. Distinct molecular pathogenesis ofearly onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population based study. Cancer Res 1999;59:2011-2017
- Clause EB, Schildkraut JM, ThompsonWB. The genetic attributable risk ofbreastand ovariancancer.Cancer 1996; 77:2318-2324 https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z
- RobsonM, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642- 1649 https://doi.org/10.1200/JCO.1998.16.5.1642
- NoguchiS, Kasugai T,MikiY,FukutomiT,EmiM,Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2- associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200-2205 https://doi.org/10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S
- Sng JH, Chang J, Feroze F, et al. The prevalence of BRCA1 mutations in Chinesen patients with early onset breast cancer and affected relatives. Br J Cancer 2000; 82:538-542 https://doi.org/10.1054/bjoc.1999.0960
- Kang HC, KimIJ,ParkJH,etal. Germline mutations of BRCA1 and BRCA2 in Korean breast families. Hum Mutat 2002;20:235-239
- Johannson OT, Idvall I, Anderson C, et al. Tumour bilogical features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-371 https://doi.org/10.1016/S0959-8049(97)89007-7
- Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514
- Johannesdottir G, Gudmundsson J, Berthorsson JT, et al. High prevalence of the 999del5 mutations in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-3665
- Thorlacius S,SigurdssonS,BjarnadottirH,etal. Study of a single BRCA2mutation with high carrierfrequency in a small population. Am J Hum Genet 1997;60:1079-1084
- Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1392-1402
- Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000;36:1200-1208 https://doi.org/10.1016/S0959-8049(00)00110-6
- PetoJ,CollinsN,BarfootR,etal. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Ins 1999;91:943-949 https://doi.org/10.1093/jnci/91.11.943
- Anglish Breast Cancer Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population- based seriesof breastcancer cases. Br J Cancer 2000; 83:1301-1308 https://doi.org/10.1054/bjoc.2000.1407
- Papelard H, de BockGH,vanEijkR,etal. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 2000;83:719-724 https://doi.org/10.1054/bjoc.2000.1331
- Loman N,Johannson O, Kristoffersson U,OlssonH,Borg A. Family history ofbreast and ovarian cancers and BRCA1 and BRCA2 mutations inapopulation-based series of early-onset breast cancer. J Natl Cancer Ins 2001;93: 1215-1223 https://doi.org/10.1093/jnci/93.16.1215
- Southey MC, Tesoriero AA, Anderson CR, et al. BRCA1 mutations and other sequence variations in a population- based sample ofAustralianwomenwith breast cancer. Br J Cancer 1999;79:34-39 https://doi.org/10.1038/sj.bjc.6690008
- MatsudaML,LiedeA,KwanE,etal. BRCA1andBRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 2002;98:596-603 https://doi.org/10.1002/ijc.10194
- Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathologic features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 2001; 7:1739-1742
- Ford D, Easton DF, Stratton M, et al. Genetic heteogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689 https://doi.org/10.1086/301749
- Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187 https://doi.org/10.1038/ng1096-185
- Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among AshkenaziJewishindividual is approximately 1%.Nat Genet 1996;14:188-190 https://doi.org/10.1038/ng1096-188
- Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revised. Cancer Res 1998;58:1588-1592
- Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breastcarcinoma occurringbeforeage 40years inwomen with andwithoutBRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335- 2345 https://doi.org/10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N
- Johannson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population- based study from southern Sweden. J Clin Oncol 1998; 16:397-404 https://doi.org/10.1200/JCO.1998.16.2.397
- Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000;18:4053-4059 https://doi.org/10.1200/JCO.2000.18.24.4053
- ChabnerE,Nixon A,Gelman R, et al. Familyhistory and treatment outcome in young women after breast-conserving surgery and radiation therapyfor early-stage breast cancer. J Clin Oncol 1998;16:2045-2051 https://doi.org/10.1200/JCO.1998.16.6.2045
- Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998; 47:129-136 https://doi.org/10.1016/S0167-8140(98)00023-1
- Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Eng J Med 1996;335: 1413-1416 https://doi.org/10.1056/NEJM199611073351901
- Verhoog LC, Bern EM,Brekelmans CT, et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 2000;18:119-124